Paper Details

  1. Home
  2. Paper Details

The role of tyrosine kinase inhibitors in the treatment of HER2+ metastatic breast cancer.

Author: CuriglianoGiuseppe, DiérasVéronqiue, Le DuFanny

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This review discusses the efficacy and safety profiles of tyrosine kinase inhibitors (TKIs) used to treat HER2+ metastatic breast cancer (MBC), with a focus on TKIs that target HER2 and other HER family receptors. The review provides guidance on adverse event management and how to incorporate TKIs into the treatment algorithm for HER2+ MBC.
Paper Details　
Original Abstract of the Article :
The introduction of trastuzumab and other subsequent human epidermal growth factor receptor 2 (HER2)-targeted therapies dramatically shifted the treatment landscape of HER2+ breast cancer, changing the natural history of the disease. There is no standard-of-care for patients with HER2+ metastatic br...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.ejca.2021.06.026

データ提供：米国国立医学図書館（NLM）

Tyrosine Kinase Inhibitors in HER2+ Metastatic Breast Cancer: A New Era in Treatment

HER2+ metastatic breast cancer is a complex and challenging condition, like a shifting desert landscape that requires strategic navigation. This research explores the role of tyrosine kinase inhibitors (TKIs) in the treatment of HER2+ metastatic breast cancer. The study reviews the efficacy data, including CNS activity, and the safety profiles of several TKIs. This research highlights the importance of understanding the intricate mechanisms of HER2 and developing targeted therapies to combat metastatic breast cancer.

TKIs: A New Frontier in HER2+ Metastatic Breast Cancer Treatment

The research suggests that TKIs play a crucial role in the treatment of HER2+ metastatic breast cancer, particularly in later lines of therapy. It's like finding a new weapon in the fight against a formidable enemy. This study provides a comprehensive overview of the various TKIs available and their potential to improve treatment outcomes for patients with HER2+ metastatic breast cancer.

Navigating Metastatic Breast Cancer: A Journey of Hope

This research offers hope for individuals with HER2+ metastatic breast cancer. The development of TKIs represents a significant advancement in the treatment of this challenging condition. This study underscores the importance of staying informed about new treatment options and actively engaging with healthcare providers to develop a personalized treatment plan.

Dr. Camel's Conclusion

This research provides valuable insights into the evolving landscape of HER2+ metastatic breast cancer treatment. The development of TKIs represents a significant step forward in the fight against this disease, offering patients new avenues for hope and improved outcomes.

Date :
  1. Date Completed 2021-11-17
  2. Date Revised 2021-11-17
Further Info :

Pubmed ID

34280871

DOI: Digital Object Identifier

10.1016/j.ejca.2021.06.026

Related Literature

Article Analysis
・Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.